Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares to two new employees at an exercise price of $8.88 per share on September 1, 2026. The options have a ten-year term with 25% vesting on the first anniversary and the remaining 75% vesting monthly over three years, subject to continued employment.